Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo

Trial Profile

A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ExFOS
  • Most Recent Events

    • 22 Apr 2018 Results (country subanalysis) assessing post teriparatide treatment patterns and effectiveness in standard clinical practise in Greek patients presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 22 Apr 2018 Results (n=735) of pooled analysis (subanalysis) of Greek patients from Efos and Exfos studies assessing non-vertebral, clinical vertebral and clinical fracture rates presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 08 Jul 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top